Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature

There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (RCC). These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafeni...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2010/687043
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566873844088832
author Nicole M. Agostino
Rebecca Gingrich
Joseph J. Drabick
author_facet Nicole M. Agostino
Rebecca Gingrich
Joseph J. Drabick
author_sort Nicole M. Agostino
collection DOAJ
description There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (RCC). These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. Bevacizumab, a monoclonal antibody directed against the ligand, VEGF, has shown activity against RCC as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon. The activity of bevacizumab in patients who had received and failed prior therapy has not been described. We report our experience in 4 patients with metastatic RCC who had failed prior cytokine, TKI, and mTOR inhibitors who were treated with bevacizumab as single agent therapy. These heavily pretreated patients sustained very prolonged periods of stable disease (median of 12 months) with very little toxicity and excellent quality of life. The activity of this agent in patients who had failed prior therapies directed against the VEGFR and mTOR suggests that therapy targeting the ligand, VEGF, is still a viable approach in these patients and deserves further study.
format Article
id doaj-art-007a095c43ca4e17883874f48cfde8ed
institution Kabale University
issn 1687-6369
1687-6377
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Advances in Urology
spelling doaj-art-007a095c43ca4e17883874f48cfde8ed2025-02-03T01:02:57ZengWileyAdvances in Urology1687-63691687-63772010-01-01201010.1155/2010/687043687043Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the LiteratureNicole M. Agostino0Rebecca Gingrich1Joseph J. Drabick2Department of Internal Medicine, Division of Hematology and Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17078, USADepartment of Internal Medicine, Division of Hematology and Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17078, USADepartment of Internal Medicine, Division of Hematology and Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17078, USAThere are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (RCC). These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. Bevacizumab, a monoclonal antibody directed against the ligand, VEGF, has shown activity against RCC as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon. The activity of bevacizumab in patients who had received and failed prior therapy has not been described. We report our experience in 4 patients with metastatic RCC who had failed prior cytokine, TKI, and mTOR inhibitors who were treated with bevacizumab as single agent therapy. These heavily pretreated patients sustained very prolonged periods of stable disease (median of 12 months) with very little toxicity and excellent quality of life. The activity of this agent in patients who had failed prior therapies directed against the VEGFR and mTOR suggests that therapy targeting the ligand, VEGF, is still a viable approach in these patients and deserves further study.http://dx.doi.org/10.1155/2010/687043
spellingShingle Nicole M. Agostino
Rebecca Gingrich
Joseph J. Drabick
Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
Advances in Urology
title Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
title_full Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
title_fullStr Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
title_full_unstemmed Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
title_short Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature
title_sort bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma a case series and review of the literature
url http://dx.doi.org/10.1155/2010/687043
work_keys_str_mv AT nicolemagostino bevacizumabdemonstratesprolongeddiseasestabilizationinpatientswithheavilypretreatedmetastaticrenalcellcarcinomaacaseseriesandreviewoftheliterature
AT rebeccagingrich bevacizumabdemonstratesprolongeddiseasestabilizationinpatientswithheavilypretreatedmetastaticrenalcellcarcinomaacaseseriesandreviewoftheliterature
AT josephjdrabick bevacizumabdemonstratesprolongeddiseasestabilizationinpatientswithheavilypretreatedmetastaticrenalcellcarcinomaacaseseriesandreviewoftheliterature